Published online September 24, 2007
doi:10.1084/jem.20070814
The Journal of Experimental Medicine, Vol. 204, No. 10, 2423-2437
The Rockefeller University Press, 0022-1007 $30.00
© 2007 Decalf et al.
Plasmacytoid dendritic cells initiate a complex chemokine and cytokine network and are a viable drug target in chronic HCV patients
Jérémie Decalf1,
Sandrine Fernandes2,
Randy Longman1,4,
Mina Ahloulay2,
Françoise Audat3,
François Lefrerre3,
Charles M. Rice4,
Stanislas Pol2, and
Matthew L. Albert1,5
1 The Laboratory of Dendritic Cell Biology, Department of Immunology, Institut Pasteur, 75724 Paris, Cedex 15, France
2 Institut National de la Santé et de la Recherche Médicale, U370, The Liver Unit, 75013 Paris, France
3 The Division of Transfusion Medicine, Necker Hospital, 75015 Paris, Cedex 15, France
4 The Rockefeller University, New York, NY 10065
5 Institut National de la Santé et de la Recherche Médicale, U818, Paris, France
CORRESPONDENCE Matthew L. Albert: albertm{at}pasteur.fr
Plasmacytoid dendritic cells (pDCs) are the professional type I interferon (IFN)-producing cells, and upon activation they traffic to lymph organs, where they bridge innate and adaptive immunity. Using multianalyte profiling (MAP), we have mapped the key chemokines and cytokines produced in response to pDC activation, taking into consideration the role of autocrine IFN, as well as paracrine effects on other innate cells (e.g., monocytes and conventional DCs). Interestingly, we identify four distinct cytokine/chemokine loops initiated by Toll-like receptor engagement. Finally, we applied this analytic approach to the study of pDC activity in chronic hepatitis C patients. Based on the activation state of pDCs in fresh blood, the lack of agonistic activity of infectious virions, the production of a broad array of cytokines/chemokines once stimulated, and the direct effects of pDCs on other PBMCs, we conclude that the pDCs from hepatitis C virus (HCV)-infected individuals are fully functional and are, indeed, a viable drug target. In sum, this study provides insight into the use of MAP technology for characterizing cytokine networks, and highlights how a rare cell type integrates the activation of other inflammatory cells. Furthermore, this work will help evaluate the therapeutic application of pDC agonists in diseases such as chronic HCV infection.
Abbreviations used: cDC, conventional DC; HAU, hemagglutinating unit; HCV, hepatitis C virus; HEV, high endothelial venule; IFNAR, interferon
/ß receptor; ICCS, intracellular cytokine stimulation; MAP, multianalyte profiling; NR, nonresponder; pDC, plasmacytoid DC; Rluc, Renilla luciferase; SVR, sustained virologic responder; TLR, Toll-like receptor.
S. Fernandes, R. Longman, and M. Ahloulay contributed equally to this paper.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
-
Cicinnati, V. R., Kang, J., Sotiropoulos, G. C., Hilgard, P., Frilling, A., Broelsch, C. E., Gerken, G., Beckebaum, S.
(2008). Altered chemotactic response of myeloid and plasmacytoid dendritic cells from patients with chronic hepatitis C: role of alpha interferon. J. Gen. Virol.
89: 1243-1253
[Abstract]
[Full Text]
-
Pascale, F., Contreras, V., Bonneau, M., Courbet, A., Chilmonczyk, S., Bevilacqua, C., Eparaud, M., Niborski, V., Riffault, S., Balazuc, A.-M., Foulon, E., Guzylack-Piriou, L., Riteau, B., Hope, J., Bertho, N., Charley, B., Schwartz-Cornil, I.
(2008). Plasmacytoid Dendritic Cells Migrate in Afferent Skin Lymph. J. Immunol.
180: 5963-5972
[Abstract]
[Full Text]
-
Barth, H., Schnober, E. K., Neumann-Haefelin, C., Thumann, C., Zeisel, M. B., Diepolder, H. M., Hu, Z., Liang, T. J., Blum, H. E., Thimme, R., Lambotin, M., Baumert, T. F.
(2008). Scavenger Receptor Class B Is Required for Hepatitis C Virus Uptake and Cross-Presentation by Human Dendritic Cells. J. Virol.
82: 3466-3479
[Abstract]
[Full Text]